Orthopedic shockwaves: a historical mechanistic overview · Lab and clinical study · 2003
How was shockwave thought to help bones and tendons heal?
This 2003 overview explains how shockwave moved from breaking up kidney stones to treating bones and tendons. In rabbits, signals linked to blood-vessel growth rose within a week, and new blood vessels formed by four weeks. Success rates reported in patients varied widely, such as 34–88% for heel pain.
Explores how shockwave works- problems covered: unhealed fractures, heel, shoulder and elbow pain
- 4
- weeks or more that new blood vessels lasted in rabbits
- 12
- year of this overview
- 2003
Good to know: A 2003 overview drawing mainly on the author's own lab, animal and patient studies.
Wang CJ Chang Gung Med J, 2003 · Read the paper ↗
Who took part
People with fractures that had not healed, heel pain, shoulder calcium deposits or tennis elbow, plus animal studies.
Side effects
The review calls complications uncommon. In animals, higher doses injured tendons and blood vessels, and one fracture experiment suggested slower healing.
All the numbers and the full appraisal
What the full paper reports.
Diverse populations with fracture nonunion, plantar fasciitis, calcific shoulder tendinopathy and lateral epicondylitis. Experimental animal findings and preliminary hip, knee and cartilage applications are separate from clinical cohorts; no unique total can be calculated.
Selected clinical success ranges1 reported outcome
Selected clinical success ranges
Qualitative finding
Reported ranges were 50–90% union, 34–88% plantar success, 47–70% shoulder success and 48–73% elbow success, without common definitions or pooling. The Abstract instead says success in these four conditions ranged from 65% to 91%. One shoulder report found 60.6% complaint-free and 57.6% complete calcium elimination. Its six controls had one slight improvement. These selected proportions do not establish a general treatment probability.
Analysis details and source
Qualitative extraction preserves the source scope.
Angiogenesis timing in animals1 reported outcome
Angiogenesis timing in animals
Qualitative finding
Rabbit eNOS/VEGF rose by one week and remained high for eight weeks; PCNA and neovessels rose at four weeks and persisted at least twelve weeks. This is preclinical evidence, not a measured patient benefit.
Analysis details and source
Qualitative extraction preserves the source scope.
Conflicting animal healing and injury1 reported outcome
Conflicting animal healing and injury
Qualitative finding
The review calls complications uncommon without a pooled denominator. Animal studies show dose-related tendon and vascular injury; one fracture experiment suggested delayed healing. These findings contradict any assumption that all energy settings are harmless. Low-energy rabbit bone results were comparable to controls. In preliminary femoral-head necrosis observations, lesion size did not significantly change despite reduced edema.
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
The review calls complications uncommon without a pooled denominator. Animal studies show dose-related tendon and vascular injury; one fracture experiment suggested delayed healing. These findings contradict any assumption that all energy settings are harmless.
Selective narrative synthesis, emphasis on the author’s studies, small controls, varying follow-up and incomplete denominators. The nonunion paragraph reports 72 enrolled but 55, 34 and 25 observed at successive times, then inconsistently says 22 patients at the last time. Elbow response categories total 44 despite 57 patients initially described. Preliminary unpublished results and historical regulatory statements are not current guidance. No structured conflict or funding declaration was located.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Selective narrative synthesis, emphasis on the author’s studies, small controls, varying follow-up and incomplete denominators. The nonunion paragraph reports 72 enrolled but 55, 34 and 25 observed at successive times, then inconsistently says 22 patients at the last time. Elbow response categories total 44 despite 57 patients initially described. Preliminary unpublished results and historical regulatory statements are not current guidance. No structured conflict or funding declaration was located.
Source-linked critical reading
mixed translational
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.
This historical review explains why treatment was investigated, but its high success percentages cannot predict your chance of recovery. The underlying studies and diagnosis matter.
What biological mechanisms and clinical applications supported orthopedic shockwave therapy in 2003?
Single-author narrative overview combining laboratory experiments, animal studies and selected clinical series. No reproducible search, eligibility criteria or formal risk-of-bias assessment. This is a historical account, not a pooled efficacy analysis.
Diverse populations with fracture nonunion, plantar fasciitis, calcific shoulder tendinopathy and lateral epicondylitis. Experimental animal findings and preliminary hip, knee and cartilage applications are separate from clinical cohorts; no unique total can be calculated.
Electrohydraulic, electromagnetic and piezoelectric generators are described. Physical energy may trigger angiogenesis and tissue responses rather than simply fragment tissue. Dose and exposure differ substantially across the cited studies.
Most selected clinical reports are uncontrolled; small control groups, low-dose comparisons and a surgery comparison appear. Differences across these designs prevent a single comparative estimate.
Clinical outcomes include union, pain, function and calcium elimination at different times. Laboratory outcomes include growth factors and neovessels. They are not validated substitutes for patient recovery.
Reported ranges were 50–90% union, 34–88% plantar success, 47–70% shoulder success and 48–73% elbow success, without common definitions or pooling. The Abstract instead says success in these four conditions ranged from 65% to 91%. One shoulder report found 60.6% complaint-free and 57.6% complete calcium elimination. Its six controls had one slight improvement. These selected proportions do not establish a general treatment probability.
The review calls complications uncommon without a pooled denominator. Animal studies show dose-related tendon and vascular injury; one fracture experiment suggested delayed healing. These findings contradict any assumption that all energy settings are harmless.
Selective narrative synthesis, emphasis on the author’s studies, small controls, varying follow-up and incomplete denominators. The nonunion paragraph reports 72 enrolled but 55, 34 and 25 observed at successive times, then inconsistently says 22 patients at the last time. Elbow response categories total 44 despite 57 patients initially described. Preliminary unpublished results and historical regulatory statements are not current guidance. No structured conflict or funding declaration was located.
Useful for understanding the historical transition from lithotripsy to biological hypotheses. It cannot determine contemporary comparative effectiveness, an optimal dose or replacement of surgery.
Test each indication in prospectively registered randomized trials with consistent success definitions, complete follow-up denominators and systematic harms; separately test whether vascular changes mediate clinical improvement.
Read the original article.
An Overview of Shock Wave Therapy in Musculoskeletal Disorders
Wang CJ. · Chang Gung Med J · 2003
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →